Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jun 22, 2022

ProMIS Neurosciences Announces Debt Amendment and Conversion

Jun 22, 2022

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

Jun 22, 2022

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

May 17, 2022

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

May 13, 2022

ProMIS Neurosciences Announces First Quarter 2022 Results

May 13, 2022

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

May 3, 2022

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Apr 28, 2022

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

Apr 19, 2022

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

Apr 7, 2022

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

  • arrow_back
  • 1…
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …27
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.